Sulindac sulfide inhibits epidermal growth factor-induced phosphorylation of extracellular-regulated kinase 1/2 and bad in human colon cancer cells

Cancer Research

Volumn 63, Issue 3, 2003, Pages 616-620

  Rice, Pamela L ^a,b,c,d   Washington, Michele ^b   Schleman, Shea ^c   Scott Beard, K ^c   Driggers, Linda J ^c   Ahnen, Dennis J ^a,b,c  

^a UNIVERSITY OF COLORADO   (United States)

^b UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAD; SULINDAC SULFIDE; UO 126;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER MORTALITY; CHEMOPROPHYLAXIS; COLORECTAL CANCER; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; UNITED STATES;

ANTINEOPLASTIC AGENTS; BCL-ASSOCIATED DEATH PROTEIN; BUTADIENES; CARRIER PROTEINS; CASPASES; COLONIC NEOPLASMS; ENZYME ACTIVATION; EPIDERMAL GROWTH FACTOR; HUMANS; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; NITRILES; PHOSPHORYLATION; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; SULINDAC; TUMOR CELLS, CULTURED;

EID: 0037311538     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Jemal, A., Thomas, A., Murray, T., and Thun, M. Cancer Statistics. 2002. CA Cancer J. Clin., 52: 23-47, 2002.
2. Marnett, L. J. Aspirin and related nonsteroidal anti-inflammatory drugs as chemopreventive agents against colon cancer. Prev. Med., 24: 103-106, 1995.
3. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., and Pariente, A. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology, 101: 635-639, 1991.
4. Giardiello, F. M., Hamilton. S. R., and Krush, A. J. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Eng. J. Med., 328: 1313-1316, 1993.
5. Nugent, K. P., Farmer, K. C., Spigelman, A. D., Williams, C. B., and Phillips, R. K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg., 80: 1618-1619, 1993.
6. Parker, A. L., Kadakia, S. C., Maccini, D. M., Cassaday, M. A., and Angueira, C. E. Disappearance of duodenal polyps in Gardner's syndrome with sulindac therapy. Am. J. Gastroenterology, 88: 93-94, 1993.
7. Spagnesi, M. T., Tonelli, F., Dolara, P., Caderni, G., Valanzano, R., Anastasi, A., and Bianchini, F. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology, 106: 362-366, 1994.
8. Steinback, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., and Levin, B. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Eng. J. Med., 342: 1946-1952, 2000.
9. Beazer-Barclay, Y., Levy, D. B., Moser, A. R., Dove. W. F., Hamilton, S, R., Vogelstein, B., and Kinzler. K. W. Sulindac suppresses tumorigenesis in the Min mouse. Carcinogenesis (Lond.), 17: 1757-1760, 1996.
10. Moorghen, M., Ince, P., Finney, K. J., Sunter, J. P., Appleton, D. R., and Watson, A. J. A protective effect of sulindac against chemically-induced primary colonic tumors in mice. J. Pathol., 156: 341-347, 1988.
11. Skinner, S. A., Penney, A. G., and O'Brien, P. E. Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch. Surg., 126: 1094-1096, 1991.
12. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendei, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
13. Dubois, R. N., Abramson, S. B., Crofford, L., Gupta, R. A., Simon, L. S., Van de Putte, L. B. A., and Lipsky, P. E. Cyclooxygenase in biology and disease. FASEB J., 12: 1063-1073, 1998.
14. Rice, P. L., Goldberg, R. J., Ray, E. C., Driggers. L. J., and Ahnen, D. J. Inhibition of extracellular signal-regulated kinase 1/2 phosphorylation and induction of apoptosis by sulindac metabolites. Cancer Res., 61: 1541-1547, 2001.
15. Thompson, W. J., Piazza, G. A., Li, H., Liu, L., Fetter, J., Zhu, B., Sperl, G., Ahnen, D., and Pamukcu. R. Exisulind induction of apoptosis involves guanosine 3′, 5[prime]-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated β-catenin. Cancer Res., 60: 3338-3342, 2000.
16. Yamamoto, Y., Yin, M. J., Lin, K. M., and Gaynor, R. B. Sulindac inhibits activation of the NF-κB pathway. J. Biol. Chem., 274: 27307-27314, 1999.
17. He, T. C., Chan, T. A., Vogelstein, B., and Kinzler, K. W. PPAR '64 is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell, 99: 335-345, 1999.
18. Soh, J. W., Mao, Y., Kim, M. G., Pamukcu, R., Li, H., Piazza, G. A., Thompson, W. J., and Weinstein, I. B. Cyclic GMP mediates apoptosis induced by sulindac derivatives via activation of c-Jun NH2-terminal kinase 1. Clin. Cancer Res., 6: 4136-4141, 2000.
19. Sebolt-Leopold, J. S., Dudley, D. T., Herrera, R., Becelaere, K. V., Wiland, A., Gowan, R. C., Tecle, H., Barrett, S. D., Bridges, A., Przybranowski, S., Leopold, W. R., and Saltiel, A. R. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat. Med., 5: 810-816, 1999.
20. Scheid, M., Schubert, K. M., and Duronio, V. Regulation of bad phosphorylation and association with Bcl-xl by the MAPK/Erk kinase. J. Biol. Chem., 274: 31108-31113, 1999.
21. Sheng, H., Shao, J., Washington, M. K., and DuBois, R. N. Prostaglandin E2 increases growth and motility of colorectal carcinoma cells. J. Biol. Chem., 276: 18075-18081, 2001.
22. Matsuura, H., Sakaue, M., Subbaramaiah, K., Kamitani, H., Eling, T. E., Dannenberg, A. J., Tanabe, T., Inoue. H., Arata, J., and Jetten, A. M. Regulation of cyclooxygenase-2 by interferon γ and transforming growth factor α in normal human epidermal keratinocytes and squamous carcinoma cells. Role of mitogen-activated protein kinases. J. Biol. Chem., 274: 29138-29148, 1999.
23. Sheng, H., Williams, C. S., Shao, J., Liang, P., DuBois, R. N., and Beauchamp, R. D. Induction of cyclooxygenase-2 by activated Ha-ras oncogene in rat-1 fibroblasts and the role of mitogen-activated protein kinase pathway. J. Biol. Chem., 273: 22120-22127, 1998.
24. Sheng, H., Shao, J., and DuBois, R. N. K-Ras-mediated increase in cyclooxygenase 2 mRNA stability involves activation of the protein kinase B. Cancer Res., 61: 2670-2675, 2001.
25. Roberts, R., B., Min, L., Washington, M. K., Olsen, S. J., Settle, S. H., Coffey, R. J., and Threadgill, D. W. Importance of epidermal growth factor receptor signaling in establishment of adenomas and maintenance of carcinomas during intestinal tumorigenesis. Proc. Natl. Acad. Sci. USA, 99: 1521-1526, 2002.
26. Torrance, C. J., Jackson, P. E., Montgomery, E., Kinzler, Vogelstein, B., Wissner, A., Nunes, M., Frost, P., and Discafani, C. M. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med., 6: 1024-1028, 2000.
27. Barnard, J. Epidermal growth factor receptor blockade. An emerging therapeutic modality in gastroenterology. Gastroenterology, 120: 1872-1874, 2001.
28. Kokoska, E. R., Smith, G., S., Miller, T. A. Nonsteroidal anti-inflammatory drugs attenuate proliferation of colonic carcinoma cells by blocking epidermal growth factor-induced Ca++ mobilization. J. Gastrointest. Surg., 4: 150-161, 2000.
29. Richter, M., Weiss, M., Weinberger, I., Furstenberger, G., and Marian. B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis (Lond.), 22: 17-25, 2001.
30. Lewis, T. S., Shapiro, P. S., and Ahn, N. G. Signal transduction through MAP kinase cascades. Adv. Cancer Res., 74: 49-139, 1998.
31. Korsmeyer, S. J. BCL-2 gene family and the regulation of programmed cell death. Cancer Res., 59: 1693s-1700s, 1999.
32. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science (Wash. DC), 284: 339-343, 1999.
33. Zha, J., Harada, H., Osipov, K., Jockel, J., Waksman, G., and Korsmeyer, S. J. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J. Biol. Chem., 272: 24101-24104, 1997.
34. Strobel, T., Tai, Y. T., Korsmeyer, S., and Cannistra, S. A. BAD partly reverses pactitaxel resistance in human ovarian cancer cells. Oncogene, 17: 2419-2427, 1998.
35. Konishi, Y., Lehtinen, M., Donovan, N., and Bonni, A. Cdc2 phosphorylation of BAD links the cell cycle to the cell death machinery. Mol. Cell, 9: 1005-1016, 2002.
36. Zhang, L., Yu, J., Park, B. H., Kinzler, K. W., and Vogelstein, B. Role of BAX in the apoptotic response to anticancer agents. Science (Wash. DC). 290: 989-992, 2000.
37. Liu, Y-Z., Boxer, L. M., and Latchman, D. S. Activation of the Bcl-2 promoter by nerve growth factor is mediated by the p42/p44 MAPK cascade. Nucleic Acids Res., 27: 2086-2090, 1999.
38. Jost, M., Huggett, T. M., Kari, C., Boise, L. H., and Rodeck, U. Epidermal growth factor receptor-dependent control of keratinocyte survival and Bcl-XL expression through a MEK-dependent pathway. J. Biol. Chem., 276: 6320-6326, 2001.
39. Hermann, C., Block, C., Geisen, C., Haas, K., Weber, C., Winde, G., Moroy, T., and Muller, O. Sulindac sulfide inhibits ras signaling. Oncogene, 17: 1769-1776, 1998.